Modulating Post-Stroke Inflammation with FDA-Approved Immunotherapies: A Literature Review
Authors:
- Eduardo Álvarez-RiveraEduardo Álvarez-Rivera
- Pamela Rodríguez-VegaPRPamela Rodríguez-Vega
- Fabiola Colón-SantiagoFabiola Colón-Santiago
- Armeliz Romero-PonceARArmeliz Romero-Ponce
- Fabiola Umpierre-LebrónFUFabiola Umpierre-Lebrón
- Paola Roig-OpioPRPaola Roig-Opio
- Aitor González-FernándezAGAitor González-Fernández
- Tiffany Rosa-ArochoTRTiffany Rosa-Arocho
- Laura Santiago-RodríguezLaura Santiago-Rodríguez
- Ana Martínez-TorresAMAna Martínez-Torres
- Gerson G. Santiago-GonzálezGSGerson G. Santiago-González
- James Llorens-MercadoJLJames Llorens-Mercado
Open Access
- 10 February 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1700
Abstract
Stroke has been a topic of extensive research due to its debilitating consequences and high mortality. New findings offer a deeper understanding of specific factors that affect post-stroke recovery and identify therapies that may facilitate this process. One such factor is post-stroke neuroinflammation, a complex and time-dependent process in which acute immune responses can cause significant secondary inflammatory damage if the process is prolonged. Microglia are neuronal immune cells that are highly reactive to cytokines in the neuroenvironment and can, in turn, affect the inflammatory cascades that originate after stroke, making them ideal candidates for immunomodulation in the brain. Many FDA-approved immunotherapies have been found to target distinct inflammatory signaling molecules and responders, including IL-6 inhibitors, IL-13 inhibitors, IL-12/IL-23 inhibitors, B-cell modulators, type I interferon inhibitors, CAR T-cell therapy, calcineurin inhibitors, complement inhibitors, and JAK-STAT pathway inhibitors. The FDA-approved immunotherapies discussed in this review demonstrate potential in modulating the immune response after stroke by targeting key inflammatory pathways involved in secondary brain injury. Future research should focus on defining optimal therapeutic windows, identifying suitable patient populations, determining the most appropriate timing of therapy, and targeting specific immune mechanisms to balance the attenuation of harmful inflammation with the preservation of reparative processes.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyeClinicalMedicine, 2024
- Microglial Inflammatory Mechanisms in Stroke: The Jury Is Still OutNeuroscience, 2024
- The efficacy and safety of interleukin-1 receptor antagonist in stroke patients: A systematic reviewJournal of Clinical Neuroscience, 2024
- Immunotherapy as a treatment for Stroke: Utilizing regulatory T cellsBrain Hemorrhages, 2023
- Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trialseClinicalMedicine, 2022
- Upadacitinib for ulcerative colitisThe Lancet, 2022
- Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 2021
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyThe Lancet, 2018
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2018
- Belimumab: A Review in Systemic Lupus ErythematosusDrugs, 2018